Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075907 · ClinicalTrials.gov registry record · Phase 3
Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents
A Phase 3 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 13
- Study locations
NCT00075907: Completed Phase 3 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00075907 is a Phase 3 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 240 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (46% lower). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00075907, a Phase 3 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness of anti-HIV drug regimens with or without a protease inhibitor (PI) in HIV infected adolescents. It will also determine if monitoring drug levels and adjusting the dose as necessary improves the effectiveness of these regimens.
Conditions Studied
Interventions
- DRUG Efavirenz + 2 NRTIs
- DRUG Lopinavir/Ritonavir + 2 NRTIs
- PROCEDURE Therapeutic Drug Monitoring
Study Locations (13)
California
- Usc La Nichd Crs - Alhambra
- Long Beach Memorial Med. Ctr., Miller Children's Hosp. - Long Beach
- Children's Hospital of Los Angeles NICHD CRS - Los Angeles
Louisiana
- Tulane/LSU Maternal/Child CRS - New Orleans
- Children's Hosp. - New Orleans
New York
- SUNY Stony Brook NICHD CRS - Stony Brook
- Bronx-Lebanon Hosp. IMPAACT CRS - The Bronx
Texas
- Children's Med. Ctr. Dallas - Dallas
- Texas Children's Hosp. CRS - Houston
Colorado
- Univ. of Colorado Denver NICHD CRS - Aurora
Illinois
- Chicago Children's CRS - Chicago
Maryland
- Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases - Baltimore
Tennessee
- St. Jude/UTHSC CRS - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00075907 record still lists
NCT00075907 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (46% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Efavirenz + 2 NRTIs is the first listed.
NCT00075907 lists 13 locations in 8 states (California, Louisiana, New York).
Frequently Asked Questions
What is clinical trial NCT00075907 about?
NCT00075907 is a clinical study titled "Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents". The purpose of this study is to compare the effectiveness of anti-HIV drug regimens with or without a protease inhibitor (PI) in HIV infected adolescents. It will also determine if monitoring drug levels and adjusting the dose as necessary improves the effectiveness of these regimens.
What is the current status of trial NCT00075907?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2004-07. Estimated completion is 2006-09.
What conditions does trial NCT00075907 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00075907?
The interventions under investigation include: Efavirenz + 2 NRTIs (DRUG), Lopinavir/Ritonavir + 2 NRTIs (DRUG), Therapeutic Drug Monitoring (PROCEDURE).
Who is sponsoring clinical trial NCT00075907?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00075907 being conducted?
This trial has 13 study locations across California, Colorado, Illinois, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00075907's enrollment target sits among peer trials
240 150th of 542 higher than 391 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia